CLU and liver disorder: For instance, some of the complement proteins identified in this study, including C1QBP, C4BPA, CLU, and SERPING1, have also been identified in proteomic analyses as potential biomarkers in metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis (56–58).